Shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) rose 1.7% on Friday . The company traded as high as $7.26 and last traded at $7.15, with a volume of 1,380,974 shares trading hands. The stock had previously closed at $7.03.

ARIA has been the topic of a number of analyst reports. JMP Securities reiterated a “buy” rating on shares of Ariad Pharmaceuticals in a research report on Monday, June 6th. Cowen and Company reissued a “buy” rating and issued a $10.00 price objective on shares of Ariad Pharmaceuticals in a research note on Monday, June 6th. William Blair reissued a “buy” rating and issued a $10.00 price objective on shares of Ariad Pharmaceuticals in a research note on Tuesday, May 24th. Jefferies Group reissued a “buy” rating and issued a $13.00 price objective on shares of Ariad Pharmaceuticals in a research note on Tuesday, May 24th. Finally, Zacks Investment Research raised Ariad Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 price objective on the stock in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $9.06.

The stock’s market cap is $1.36 billion. The stock’s 50-day moving average is $7.80 and its 200 day moving average is $6.62.

Ariad Pharmaceuticals (NASDAQ:ARIA) last posted its quarterly earnings data on Tuesday, May 10th. The pharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.04. The company had revenue of $35.60 million for the quarter, compared to the consensus estimate of $43.06 million. During the same quarter last year, the business earned ($0.28) EPS. Ariad Pharmaceuticals’s revenue was up 48.3% on a year-over-year basis. On average, equities research analysts forecast that Ariad Pharmaceuticals Inc. will post ($0.60) EPS for the current fiscal year.

In other Ariad Pharmaceuticals news, SVP Hugh M. Cole sold 6,012 shares of the firm’s stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $7.05, for a total transaction of $42,384.60. Following the transaction, the senior vice president now owns 29,262 shares in the company, valued at approximately $206,297.10. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Massimo Radaelli sold 108,569 shares of the firm’s stock in a transaction on Tuesday, June 14th. The stock was sold at an average price of $8.25, for a total value of $895,694.25. Following the transaction, the director now owns 128,088 shares in the company, valued at approximately $1,056,726. The disclosure for this sale can be found here.

A number of institutional investors recently bought and sold shares of the company. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp raised its position in Ariad Pharmaceuticals by 13.1% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 1,418,866 shares of the pharmaceutical company’s stock worth $8,868,000 after buying an additional 164,580 shares during the period. New York State Common Retirement Fund raised its position in Ariad Pharmaceuticals by 18.0% in the fourth quarter. New York State Common Retirement Fund now owns 193,180 shares of the pharmaceutical company’s stock worth $1,207,000 after buying an additional 29,480 shares during the period. ProShare Advisors LLC raised its position in Ariad Pharmaceuticals by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 176,600 shares of the pharmaceutical company’s stock worth $1,104,000 after buying an additional 16,552 shares during the period. Rhumbline Advisers raised its position in Ariad Pharmaceuticals by 7.8% in the fourth quarter. Rhumbline Advisers now owns 174,193 shares of the pharmaceutical company’s stock worth $1,089,000 after buying an additional 12,560 shares during the period. Finally, OppenheimerFunds Inc. raised its position in Ariad Pharmaceuticals by 0.5% in the fourth quarter. OppenheimerFunds Inc. now owns 1,862,400 shares of the pharmaceutical company’s stock worth $11,640,000 after buying an additional 9,480 shares during the period.

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.